What is HC Wainwright’s Estimate for ARQT Q1 Earnings?

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) – Analysts at HC Wainwright upped their Q1 2025 earnings per share estimates for shares of Arcutis Biotherapeutics in a research note issued to investors on Wednesday, February 26th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings of ($0.22) per share for the quarter, up from their previous estimate of ($0.30). HC Wainwright currently has a “Buy” rating and a $19.00 target price on the stock. The consensus estimate for Arcutis Biotherapeutics’ current full-year earnings is ($1.33) per share. HC Wainwright also issued estimates for Arcutis Biotherapeutics’ Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.81) EPS, FY2026 earnings at ($0.03) EPS and FY2029 earnings at $2.35 EPS.

Arcutis Biotherapeutics (NASDAQ:ARQT) last posted its earnings results on Tuesday, February 25th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.19. Arcutis Biotherapeutics had a negative return on equity of 119.11% and a negative net margin of 140.97%. The company had revenue of $71.36 million for the quarter, compared to the consensus estimate of $60.52 million.

Other equities analysts have also recently issued reports about the company. The Goldman Sachs Group lifted their price objective on Arcutis Biotherapeutics from $13.00 to $15.00 and gave the company a “neutral” rating in a report on Thursday, February 27th. Guggenheim restated a “buy” rating on shares of Arcutis Biotherapeutics in a research report on Monday, February 24th. Needham & Company LLC reiterated a “buy” rating and set a $20.00 price target on shares of Arcutis Biotherapeutics in a research report on Wednesday, February 26th. Finally, Mizuho raised their target price on Arcutis Biotherapeutics from $20.00 to $21.00 and gave the company an “outperform” rating in a report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $18.00.

Arcutis Biotherapeutics Stock Up 4.4 %

Shares of ARQT opened at $13.40 on Monday. The company has a current ratio of 2.46, a quick ratio of 2.38 and a debt-to-equity ratio of 0.67. Arcutis Biotherapeutics has a 12 month low of $6.99 and a 12 month high of $16.20. The firm’s 50 day moving average is $13.49 and its 200-day moving average is $11.51. The stock has a market capitalization of $1.59 billion, a PE ratio of -7.49 and a beta of 1.29.

Insider Transactions at Arcutis Biotherapeutics

In other Arcutis Biotherapeutics news, insider Todd Franklin Watanabe sold 15,000 shares of Arcutis Biotherapeutics stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $15.17, for a total value of $227,550.00. Following the completion of the sale, the insider now directly owns 823,430 shares in the company, valued at approximately $12,491,433.10. The trade was a 1.79 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Howard G. Welgus sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $13.00, for a total transaction of $130,000.00. Following the sale, the director now directly owns 131,944 shares of the company’s stock, valued at approximately $1,715,272. This trade represents a 7.05 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 57,848 shares of company stock worth $797,648. Company insiders own 9.50% of the company’s stock.

Institutional Trading of Arcutis Biotherapeutics

Several institutional investors have recently made changes to their positions in ARQT. GF Fund Management CO. LTD. purchased a new position in Arcutis Biotherapeutics in the fourth quarter valued at about $34,000. Point72 DIFC Ltd purchased a new position in shares of Arcutis Biotherapeutics during the 3rd quarter valued at $25,000. Venturi Wealth Management LLC bought a new position in shares of Arcutis Biotherapeutics during the 4th quarter worth $46,000. Cibc World Markets Corp purchased a new stake in Arcutis Biotherapeutics in the 4th quarter worth about $140,000. Finally, Erste Asset Management GmbH bought a new stake in Arcutis Biotherapeutics in the 3rd quarter valued at about $104,000.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.